Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma

Masaya Yotsukura, Hiroyuki Yasuda, Takao Shigenobu, Kaoru Kaseda, Kyohei Masai, Yuichiro Hayashi, Tomoyuki Hishida, Takashi Ohtsuka, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku, Hisao Asamura

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives Over the past decade, the biological and clinical characteristics of lung cancer with epidermal growth factor receptor (EGFR) mutation have been well studied. However, most studies have focused on advanced inoperable cancer, and not on resected early-stage lung adenocarcinoma. We aimed to elucidate the differences in the clinicopathological characteristics and postoperative prognosis according to the EGFR mutation status in early-stage lung adenocarcinoma. Materials and methods We retrospectively collected clinical and pathological data from 369 patients with pathological stage I or II lung adenocarcinoma who underwent complete resection. Clinicopathological characteristics and postoperative prognosis were compared depending on the EGFR mutation status, using the Chi-squared test and the log-rank test, respectively. Results and conclusion Of the 369 patients, 160 (43.3%) had EGFR mutation, of which 64 (40.0%) were exon 19 deletion (Del-19) and 90 (56.3%) were exon 21 point mutation L858R. Although there was no difference in overall survival (OS) between patients with and without EGFR mutation (p = 0.086), tumors with EGFR mutation were associated with a lower consolidation to tumor ratio (CTR) (p < 0.001) and a higher incidence of a lepidic growth pattern by pathological evaluation (p < 0.001) compared to those without EGFR mutation. Among tumors with EGFR mutation, there was no difference in OS (p = 0.140) between Del-19 and L858R. Tumors with L858R were associated with a lower CTR (p = 0.046), and tended to have a higher incidence of a lepidic growth pattern by pathological evaluation (p = 0.073) compared to those with Del-19. In conclusion, although EGFR mutation status was not a prognostic indicator after surgery in early-stage lung adenocarcinoma, L858R and Del-19 had different radiological and pathological features.

Original languageEnglish
Pages (from-to)45-51
Number of pages7
JournalLung Cancer
Volume109
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Epidermal Growth Factor Receptor
Mutation
Neoplasms
Exons
Adenocarcinoma of lung
Survival
Incidence
Growth
Point Mutation
Lung Neoplasms

Keywords

  • EGFR mutation
  • Lung cancer
  • Prognostic factor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma. / Yotsukura, Masaya; Yasuda, Hiroyuki; Shigenobu, Takao; Kaseda, Kaoru; Masai, Kyohei; Hayashi, Yuichiro; Hishida, Tomoyuki; Ohtsuka, Takashi; Naoki, Katsuhiko; Soejima, Kenzo; Betsuyaku, Tomoko; Asamura, Hisao.

In: Lung Cancer, Vol. 109, 01.07.2017, p. 45-51.

Research output: Contribution to journalArticle

@article{35129dda4452410081833ae46bb4e836,
title = "Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma",
abstract = "Objectives Over the past decade, the biological and clinical characteristics of lung cancer with epidermal growth factor receptor (EGFR) mutation have been well studied. However, most studies have focused on advanced inoperable cancer, and not on resected early-stage lung adenocarcinoma. We aimed to elucidate the differences in the clinicopathological characteristics and postoperative prognosis according to the EGFR mutation status in early-stage lung adenocarcinoma. Materials and methods We retrospectively collected clinical and pathological data from 369 patients with pathological stage I or II lung adenocarcinoma who underwent complete resection. Clinicopathological characteristics and postoperative prognosis were compared depending on the EGFR mutation status, using the Chi-squared test and the log-rank test, respectively. Results and conclusion Of the 369 patients, 160 (43.3{\%}) had EGFR mutation, of which 64 (40.0{\%}) were exon 19 deletion (Del-19) and 90 (56.3{\%}) were exon 21 point mutation L858R. Although there was no difference in overall survival (OS) between patients with and without EGFR mutation (p = 0.086), tumors with EGFR mutation were associated with a lower consolidation to tumor ratio (CTR) (p < 0.001) and a higher incidence of a lepidic growth pattern by pathological evaluation (p < 0.001) compared to those without EGFR mutation. Among tumors with EGFR mutation, there was no difference in OS (p = 0.140) between Del-19 and L858R. Tumors with L858R were associated with a lower CTR (p = 0.046), and tended to have a higher incidence of a lepidic growth pattern by pathological evaluation (p = 0.073) compared to those with Del-19. In conclusion, although EGFR mutation status was not a prognostic indicator after surgery in early-stage lung adenocarcinoma, L858R and Del-19 had different radiological and pathological features.",
keywords = "EGFR mutation, Lung cancer, Prognostic factor",
author = "Masaya Yotsukura and Hiroyuki Yasuda and Takao Shigenobu and Kaoru Kaseda and Kyohei Masai and Yuichiro Hayashi and Tomoyuki Hishida and Takashi Ohtsuka and Katsuhiko Naoki and Kenzo Soejima and Tomoko Betsuyaku and Hisao Asamura",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.lungcan.2017.04.014",
language = "English",
volume = "109",
pages = "45--51",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma

AU - Yotsukura, Masaya

AU - Yasuda, Hiroyuki

AU - Shigenobu, Takao

AU - Kaseda, Kaoru

AU - Masai, Kyohei

AU - Hayashi, Yuichiro

AU - Hishida, Tomoyuki

AU - Ohtsuka, Takashi

AU - Naoki, Katsuhiko

AU - Soejima, Kenzo

AU - Betsuyaku, Tomoko

AU - Asamura, Hisao

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Objectives Over the past decade, the biological and clinical characteristics of lung cancer with epidermal growth factor receptor (EGFR) mutation have been well studied. However, most studies have focused on advanced inoperable cancer, and not on resected early-stage lung adenocarcinoma. We aimed to elucidate the differences in the clinicopathological characteristics and postoperative prognosis according to the EGFR mutation status in early-stage lung adenocarcinoma. Materials and methods We retrospectively collected clinical and pathological data from 369 patients with pathological stage I or II lung adenocarcinoma who underwent complete resection. Clinicopathological characteristics and postoperative prognosis were compared depending on the EGFR mutation status, using the Chi-squared test and the log-rank test, respectively. Results and conclusion Of the 369 patients, 160 (43.3%) had EGFR mutation, of which 64 (40.0%) were exon 19 deletion (Del-19) and 90 (56.3%) were exon 21 point mutation L858R. Although there was no difference in overall survival (OS) between patients with and without EGFR mutation (p = 0.086), tumors with EGFR mutation were associated with a lower consolidation to tumor ratio (CTR) (p < 0.001) and a higher incidence of a lepidic growth pattern by pathological evaluation (p < 0.001) compared to those without EGFR mutation. Among tumors with EGFR mutation, there was no difference in OS (p = 0.140) between Del-19 and L858R. Tumors with L858R were associated with a lower CTR (p = 0.046), and tended to have a higher incidence of a lepidic growth pattern by pathological evaluation (p = 0.073) compared to those with Del-19. In conclusion, although EGFR mutation status was not a prognostic indicator after surgery in early-stage lung adenocarcinoma, L858R and Del-19 had different radiological and pathological features.

AB - Objectives Over the past decade, the biological and clinical characteristics of lung cancer with epidermal growth factor receptor (EGFR) mutation have been well studied. However, most studies have focused on advanced inoperable cancer, and not on resected early-stage lung adenocarcinoma. We aimed to elucidate the differences in the clinicopathological characteristics and postoperative prognosis according to the EGFR mutation status in early-stage lung adenocarcinoma. Materials and methods We retrospectively collected clinical and pathological data from 369 patients with pathological stage I or II lung adenocarcinoma who underwent complete resection. Clinicopathological characteristics and postoperative prognosis were compared depending on the EGFR mutation status, using the Chi-squared test and the log-rank test, respectively. Results and conclusion Of the 369 patients, 160 (43.3%) had EGFR mutation, of which 64 (40.0%) were exon 19 deletion (Del-19) and 90 (56.3%) were exon 21 point mutation L858R. Although there was no difference in overall survival (OS) between patients with and without EGFR mutation (p = 0.086), tumors with EGFR mutation were associated with a lower consolidation to tumor ratio (CTR) (p < 0.001) and a higher incidence of a lepidic growth pattern by pathological evaluation (p < 0.001) compared to those without EGFR mutation. Among tumors with EGFR mutation, there was no difference in OS (p = 0.140) between Del-19 and L858R. Tumors with L858R were associated with a lower CTR (p = 0.046), and tended to have a higher incidence of a lepidic growth pattern by pathological evaluation (p = 0.073) compared to those with Del-19. In conclusion, although EGFR mutation status was not a prognostic indicator after surgery in early-stage lung adenocarcinoma, L858R and Del-19 had different radiological and pathological features.

KW - EGFR mutation

KW - Lung cancer

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=85018987095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018987095&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2017.04.014

DO - 10.1016/j.lungcan.2017.04.014

M3 - Article

C2 - 28577949

AN - SCOPUS:85018987095

VL - 109

SP - 45

EP - 51

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -